| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuropilin-2 | 11 | 2024 | 40 | 2.690 |
Why?
|
| Prostatic Neoplasms | 15 | 2023 | 418 | 2.380 |
Why?
|
| Integrin beta1 | 8 | 2025 | 32 | 2.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 11 | 2024 | 213 | 1.880 |
Why?
|
| Integrin alpha6beta1 | 4 | 2015 | 34 | 1.270 |
Why?
|
| Neoplastic Stem Cells | 9 | 2020 | 203 | 1.200 |
Why?
|
| Integrin beta4 | 3 | 2024 | 32 | 1.150 |
Why?
|
| Signal Transduction | 18 | 2025 | 3035 | 1.100 |
Why?
|
| Cell Line, Tumor | 19 | 2025 | 1469 | 0.960 |
Why?
|
| Adaptor Proteins, Signal Transducing | 6 | 2024 | 429 | 0.910 |
Why?
|
| Breast Neoplasms | 8 | 2025 | 1198 | 0.870 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2024 | 8 | 0.870 |
Why?
|
| Receptor, IGF Type 1 | 4 | 2013 | 30 | 0.800 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2025 | 525 | 0.720 |
Why?
|
| Adenocarcinoma | 4 | 2016 | 348 | 0.700 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2024 | 67 | 0.680 |
Why?
|
| Phosphoproteins | 8 | 2024 | 220 | 0.660 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2002 | 126 | 0.590 |
Why?
|
| Integrins | 4 | 2008 | 109 | 0.570 |
Why?
|
| Transcription Factors | 7 | 2019 | 1513 | 0.570 |
Why?
|
| Integrin alpha6 | 3 | 2023 | 20 | 0.530 |
Why?
|
| Neoplasms | 6 | 2024 | 1364 | 0.520 |
Why?
|
| Muscle, Skeletal | 4 | 2002 | 741 | 0.520 |
Why?
|
| Focal Adhesions | 3 | 2012 | 24 | 0.520 |
Why?
|
| Radiation Tolerance | 4 | 2024 | 52 | 0.510 |
Why?
|
| Neovascularization, Pathologic | 3 | 2012 | 140 | 0.510 |
Why?
|
| Autocrine Communication | 2 | 2013 | 30 | 0.500 |
Why?
|
| Mammary Glands, Animal | 2 | 2019 | 79 | 0.490 |
Why?
|
| Polycomb Repressive Complex 1 | 2 | 2014 | 31 | 0.490 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 198 | 0.480 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2016 | 60 | 0.480 |
Why?
|
| Protein Kinase C | 3 | 2012 | 102 | 0.450 |
Why?
|
| Antineoplastic Agents | 6 | 2023 | 663 | 0.450 |
Why?
|
| Cell Movement | 3 | 2016 | 453 | 0.430 |
Why?
|
| Insulin | 3 | 2002 | 686 | 0.430 |
Why?
|
| Cell Proliferation | 3 | 2018 | 988 | 0.420 |
Why?
|
| Animals | 24 | 2024 | 20660 | 0.420 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2002 | 217 | 0.400 |
Why?
|
| RNA Splicing | 1 | 2014 | 162 | 0.400 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2013 | 83 | 0.390 |
Why?
|
| Mice | 17 | 2024 | 10844 | 0.390 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 206 | 0.360 |
Why?
|
| Humans | 38 | 2025 | 63446 | 0.350 |
Why?
|
| Morphogenesis | 1 | 2011 | 113 | 0.350 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2006 | 171 | 0.340 |
Why?
|
| Cell Adhesion | 7 | 2017 | 209 | 0.330 |
Why?
|
| RNA Interference | 5 | 2018 | 618 | 0.320 |
Why?
|
| Laminin | 4 | 2015 | 78 | 0.320 |
Why?
|
| Thrombospondin 1 | 1 | 2009 | 6 | 0.310 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2009 | 35 | 0.310 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2011 | 642 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2018 | 337 | 0.270 |
Why?
|
| B7-H1 Antigen | 2 | 2024 | 57 | 0.270 |
Why?
|
| Epithelial Cells | 3 | 2017 | 390 | 0.270 |
Why?
|
| Genetic Variation | 1 | 2009 | 383 | 0.260 |
Why?
|
| Mice, Transgenic | 4 | 2013 | 1277 | 0.260 |
Why?
|
| Tyrosine | 2 | 2010 | 94 | 0.260 |
Why?
|
| Cytoskeletal Proteins | 3 | 2002 | 200 | 0.260 |
Why?
|
| Hyaluronan Receptors | 2 | 2019 | 35 | 0.260 |
Why?
|
| RNA, Small Interfering | 4 | 2014 | 921 | 0.250 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2006 | 22 | 0.240 |
Why?
|
| Focal Adhesion Kinase 1 | 4 | 2012 | 13 | 0.240 |
Why?
|
| Trans-Activators | 3 | 2024 | 311 | 0.240 |
Why?
|
| Extracellular Matrix | 4 | 2017 | 139 | 0.240 |
Why?
|
| GATA3 Transcription Factor | 1 | 2025 | 17 | 0.240 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 4 | 2011 | 16 | 0.230 |
Why?
|
| Mice, Inbred NOD | 3 | 2018 | 525 | 0.230 |
Why?
|
| Female | 15 | 2025 | 32878 | 0.230 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2016 | 33 | 0.230 |
Why?
|
| Mice, Knockout | 4 | 2019 | 2109 | 0.230 |
Why?
|
| Phosphorylation | 5 | 2010 | 936 | 0.230 |
Why?
|
| Transfection | 4 | 2018 | 694 | 0.230 |
Why?
|
| Receptors, Somatomedin | 1 | 2004 | 10 | 0.220 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 27 | 0.220 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 130 | 0.220 |
Why?
|
| Prostate | 1 | 2004 | 90 | 0.210 |
Why?
|
| Uridine Diphosphate Glucuronic Acid | 1 | 2023 | 9 | 0.210 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2023 | 9 | 0.210 |
Why?
|
| Cell Adhesion Molecules | 1 | 2024 | 92 | 0.210 |
Why?
|
| Male | 15 | 2023 | 29889 | 0.210 |
Why?
|
| Nitric Oxide | 1 | 2024 | 174 | 0.210 |
Why?
|
| Nanoparticles | 2 | 2020 | 513 | 0.210 |
Why?
|
| Coenzyme A Ligases | 2 | 2025 | 13 | 0.200 |
Why?
|
| Oxidative Stress | 1 | 2024 | 298 | 0.190 |
Why?
|
| Transplantation, Heterologous | 2 | 2013 | 229 | 0.190 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1617 | 0.190 |
Why?
|
| Cell Differentiation | 3 | 2020 | 1353 | 0.190 |
Why?
|
| Sarcolemma | 1 | 2002 | 10 | 0.190 |
Why?
|
| Tumor Microenvironment | 2 | 2013 | 158 | 0.190 |
Why?
|
| Zinc Finger Protein GLI1 | 2 | 2013 | 31 | 0.180 |
Why?
|
| Enzyme Activation | 3 | 2012 | 381 | 0.180 |
Why?
|
| Myosin Heavy Chains | 1 | 2002 | 44 | 0.180 |
Why?
|
| Apoptosis | 5 | 2018 | 1079 | 0.180 |
Why?
|
| src-Family Kinases | 2 | 2017 | 64 | 0.180 |
Why?
|
| Cell Division | 4 | 2009 | 450 | 0.180 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2002 | 94 | 0.170 |
Why?
|
| Neoplasm Proteins | 2 | 2024 | 281 | 0.170 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2002 | 263 | 0.170 |
Why?
|
| Cells, Cultured | 4 | 2011 | 2157 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 325 | 0.170 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2016 | 141 | 0.170 |
Why?
|
| Transcription, Genetic | 2 | 2016 | 878 | 0.160 |
Why?
|
| Cell Survival | 3 | 2018 | 575 | 0.160 |
Why?
|
| Rad51 Recombinase | 1 | 2019 | 29 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 190 | 0.150 |
Why?
|
| Protein Binding | 4 | 2023 | 1603 | 0.150 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 673 | 0.150 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2018 | 14 | 0.150 |
Why?
|
| Neuropilins | 2 | 2019 | 8 | 0.150 |
Why?
|
| Mice, SCID | 2 | 2018 | 519 | 0.150 |
Why?
|
| Paxillin | 3 | 2002 | 9 | 0.150 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2018 | 16 | 0.140 |
Why?
|
| Alternative Splicing | 1 | 2019 | 127 | 0.140 |
Why?
|
| Glutathione Peroxidase | 1 | 2017 | 28 | 0.140 |
Why?
|
| Stem Cells | 1 | 2019 | 259 | 0.140 |
Why?
|
| Integrin alpha6beta4 | 1 | 2017 | 44 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2024 | 687 | 0.130 |
Why?
|
| Ligands | 3 | 2015 | 416 | 0.130 |
Why?
|
| Biosensing Techniques | 1 | 2018 | 119 | 0.130 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 93 | 0.120 |
Why?
|
| Disease Progression | 2 | 2012 | 1172 | 0.120 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 41 | 0.120 |
Why?
|
| Bevacizumab | 1 | 2016 | 59 | 0.120 |
Why?
|
| Pyrroles | 1 | 2016 | 52 | 0.120 |
Why?
|
| Cell Line | 4 | 2018 | 2040 | 0.120 |
Why?
|
| Indoles | 1 | 2016 | 110 | 0.120 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 361 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 77 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2016 | 117 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2015 | 20 | 0.110 |
Why?
|
| Gene Editing | 1 | 2019 | 321 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2016 | 130 | 0.110 |
Why?
|
| CD24 Antigen | 1 | 2014 | 18 | 0.110 |
Why?
|
| Capillary Permeability | 1 | 2013 | 16 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2013 | 11 | 0.100 |
Why?
|
| Mice, Nude | 1 | 2013 | 277 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2013 | 108 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2006 | 374 | 0.100 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 68 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 84 | 0.090 |
Why?
|
| Actin Cytoskeleton | 2 | 2002 | 76 | 0.090 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 190 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2018 | 319 | 0.090 |
Why?
|
| Piperazines | 2 | 2024 | 81 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2009 | 200 | 0.090 |
Why?
|
| Immunoblotting | 1 | 2011 | 204 | 0.090 |
Why?
|
| Integrin alpha5 | 1 | 2010 | 7 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 435 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 883 | 0.080 |
Why?
|
| Oligopeptides | 2 | 2018 | 132 | 0.080 |
Why?
|
| Fibronectins | 3 | 2008 | 43 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 542 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 85 | 0.080 |
Why?
|
| Cytoprotection | 1 | 2009 | 18 | 0.080 |
Why?
|
| Umbilical Veins | 1 | 2009 | 12 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 1186 | 0.080 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 182 | 0.080 |
Why?
|
| Molecular Chaperones | 1 | 2009 | 99 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 896 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 207 | 0.080 |
Why?
|
| Tosyl Compounds | 1 | 2008 | 5 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2009 | 65 | 0.080 |
Why?
|
| Anilides | 1 | 2008 | 18 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2023 | 1537 | 0.070 |
Why?
|
| Androgens | 1 | 2008 | 48 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2010 | 489 | 0.070 |
Why?
|
| Nitriles | 1 | 2008 | 70 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2008 | 69 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 175 | 0.070 |
Why?
|
| Receptors, Growth Factor | 1 | 2007 | 19 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2009 | 187 | 0.070 |
Why?
|
| Protein Isoforms | 2 | 2019 | 197 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 676 | 0.060 |
Why?
|
| Mitochondria | 1 | 2009 | 371 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2006 | 17 | 0.060 |
Why?
|
| Protein Phosphatase 2 | 1 | 2006 | 11 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2006 | 59 | 0.060 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 36 | 0.060 |
Why?
|
| CHO Cells | 1 | 2006 | 189 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 3396 | 0.060 |
Why?
|
| Cricetinae | 1 | 2006 | 367 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 455 | 0.060 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2024 | 13 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2006 | 276 | 0.060 |
Why?
|
| Imidazoles | 1 | 2024 | 82 | 0.060 |
Why?
|
| Immunoconjugates | 1 | 2024 | 90 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 70 | 0.050 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2004 | 55 | 0.050 |
Why?
|
| TRPC6 Cation Channel | 1 | 2023 | 6 | 0.050 |
Why?
|
| Uridine Diphosphate Xylose | 1 | 2023 | 6 | 0.050 |
Why?
|
| TRPC Cation Channels | 1 | 2023 | 11 | 0.050 |
Why?
|
| Neuropilin-1 | 1 | 2023 | 12 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2023 | 103 | 0.050 |
Why?
|
| Chromones | 1 | 2002 | 19 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-crk | 1 | 2002 | 2 | 0.050 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2002 | 5 | 0.050 |
Why?
|
| Creatine Kinase, MM Form | 1 | 2002 | 4 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 2002 | 41 | 0.050 |
Why?
|
| Androstadienes | 1 | 2002 | 41 | 0.050 |
Why?
|
| Receptor, Insulin | 1 | 2002 | 50 | 0.050 |
Why?
|
| Morpholines | 1 | 2002 | 89 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2002 | 140 | 0.050 |
Why?
|
| Protein Kinase C-alpha | 1 | 2002 | 16 | 0.050 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 160 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2016 | 1991 | 0.050 |
Why?
|
| Cytoskeleton | 1 | 2002 | 139 | 0.050 |
Why?
|
| Kinetics | 1 | 2002 | 763 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 226 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 373 | 0.040 |
Why?
|
| Calcium | 1 | 2023 | 575 | 0.040 |
Why?
|
| Platinum | 1 | 2019 | 20 | 0.040 |
Why?
|
| Microscopy, Video | 1 | 2019 | 38 | 0.040 |
Why?
|
| Homologous Recombination | 1 | 2019 | 28 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 58 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 750 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 864 | 0.040 |
Why?
|
| Rats | 1 | 2002 | 1980 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2187 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2017 | 65 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 456 | 0.030 |
Why?
|
| DNA Repair | 1 | 2019 | 248 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 72 | 0.030 |
Why?
|
| Models, Biological | 2 | 2016 | 1180 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 674 | 0.030 |
Why?
|
| Iron | 1 | 2017 | 148 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2002 | 895 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2016 | 101 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 265 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 278 | 0.030 |
Why?
|
| Phenotype | 1 | 2018 | 1207 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2015 | 176 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 145 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 237 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 1331 | 0.030 |
Why?
|
| Binding Sites | 1 | 2015 | 905 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 1592 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 83 | 0.020 |
Why?
|
| Epithelium | 1 | 2009 | 96 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2008 | 15 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 52 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 284 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2008 | 76 | 0.020 |
Why?
|
| Forecasting | 1 | 2007 | 232 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 509 | 0.020 |
Why?
|
| Rhodamines | 1 | 2005 | 20 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2005 | 132 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 200 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 5353 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 5680 | 0.010 |
Why?
|
| Aged | 1 | 2009 | 14449 | 0.010 |
Why?
|
| Middle Aged | 1 | 2009 | 17615 | 0.010 |
Why?
|